Medecins Sans Frontieres (MSF), an International Medical Humanitarian Organization has called for a reduction in the high price of the new Tuberculosis drug Delamanid.

According to MSF in Geneva on Thursday, the Japanese pharmaceutical company, Otsuka said that it would make Delamanid available to some developing countries at a price of US$1,700 per treatment course but has registered Delamanid in only four countries that have low burden burden of the disease.

MSF, the non-for-profit-organisation noted that with the reduction, countries that are eligible for funding from the Global Fund to fight Aids, Tuberculosis and Malaria would be able to sell delamanid for $1,700 per treatment course.

 

No Comments

Leave a Comment